DE19963859A1 - Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen - Google Patents

Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

Info

Publication number
DE19963859A1
DE19963859A1 DE19963859A DE19963859A DE19963859A1 DE 19963859 A1 DE19963859 A1 DE 19963859A1 DE 19963859 A DE19963859 A DE 19963859A DE 19963859 A DE19963859 A DE 19963859A DE 19963859 A1 DE19963859 A1 DE 19963859A1
Authority
DE
Germany
Prior art keywords
component
fusion proteins
protein
recombinant fusion
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19963859A
Other languages
German (de)
English (en)
Inventor
Juerg Tschopp
Pascal Schneider
Nils Holler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget Switzerland SA
Original Assignee
Apotech Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7935052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19963859(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotech Research and Development Ltd filed Critical Apotech Research and Development Ltd
Priority to DE19963859A priority Critical patent/DE19963859A1/de
Priority to JP2001550394A priority patent/JP5031165B2/ja
Priority to AT00987425T priority patent/ATE397076T1/de
Priority to DE50015185T priority patent/DE50015185D1/de
Priority to PL358456A priority patent/PL204277B1/pl
Priority to HU0203628A priority patent/HU229204B1/hu
Priority to PT00987425T priority patent/PT1246925E/pt
Priority to IL15021500A priority patent/IL150215A0/xx
Priority to EP00987425A priority patent/EP1246925B1/de
Priority to AU23673/01A priority patent/AU783833B2/en
Priority to CA2395632A priority patent/CA2395632C/en
Priority to BRPI0017054A priority patent/BRPI0017054B1/pt
Priority to DK00987425T priority patent/DK1246925T3/da
Priority to EP08103225A priority patent/EP1985706A3/de
Priority to KR1020027008522A priority patent/KR100767980B1/ko
Priority to PCT/EP2000/013032 priority patent/WO2001049866A1/de
Priority to ES00987425T priority patent/ES2307550T3/es
Priority to CNB008181004A priority patent/CN100385002C/zh
Publication of DE19963859A1 publication Critical patent/DE19963859A1/de
Priority to IL150215A priority patent/IL150215A/en
Priority to ZA200205069A priority patent/ZA200205069B/xx
Priority to US10/185,425 priority patent/US7385032B2/en
Priority to US10/871,776 priority patent/US20040235117A1/en
Priority to US12/131,478 priority patent/US20090053252A1/en
Priority to CY20081100738T priority patent/CY1108195T1/el
Priority to US13/077,512 priority patent/US20120009211A1/en
Priority to US13/764,322 priority patent/US20130202552A1/en
Priority to US14/264,402 priority patent/US20150004129A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
DE19963859A 1999-12-30 1999-12-30 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen Withdrawn DE19963859A1 (de)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DE19963859A DE19963859A1 (de) 1999-12-30 1999-12-30 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CNB008181004A CN100385002C (zh) 1999-12-30 2000-12-20 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物
DK00987425T DK1246925T3 (da) 1999-12-30 2000-12-20 DI- eller oligomer af en dimer, trimer, kvadromer eller pentamer af rekombinante fusionsproteiner
KR1020027008522A KR100767980B1 (ko) 1999-12-30 2000-12-20 재조합 융합 단백질의 이량체, 삼량체, 사량체 또는 오량체의 바이머 또는 올리고머
DE50015185T DE50015185D1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
PL358456A PL204277B1 (pl) 1999-12-30 2000-12-20 Białko fuzyjne, jego bi-lub oligomer, ich zastosowania, sekwencja DNA, wektor ekspresyjny, komórka gospodarza oraz środek farmaceutyczny
HU0203628A HU229204B1 (hu) 1999-12-30 2000-12-20 Rekombináns fúziós fehérjék dimerje, trimerje, tetramerje vagy pentamerje által alkotott bimer vagy oligomer
PT00987425T PT1246925E (pt) 1999-12-30 2000-12-20 Bi - ou oligómero de um di -, tri-, quattro - ou pentâmero de proteínas de fusão recombinantes
IL15021500A IL150215A0 (en) 1999-12-30 2000-12-20 Di-or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
EP00987425A EP1246925B1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
AU23673/01A AU783833B2 (en) 1999-12-30 2000-12-20 Di- or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
CA2395632A CA2395632C (en) 1999-12-30 2000-12-20 A bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
BRPI0017054A BRPI0017054B1 (pt) 1999-12-30 2000-12-20 proteína de fusão recombinante, oligômeros e uso dos mesmos, bem como sequência de dna recombinante
JP2001550394A JP5031165B2 (ja) 1999-12-30 2000-12-20 組み換え融合タンパク質のダイマー、トリマー、クアトロマー又はペンタマーのバイマー又はオリゴマー
EP08103225A EP1985706A3 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
AT00987425T ATE397076T1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
PCT/EP2000/013032 WO2001049866A1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen
ES00987425T ES2307550T3 (es) 1999-12-30 2000-12-20 Di-u oligomero de un di-, tri-,tetra- o pentametro de proteinas de fusion recombinantes.
IL150215A IL150215A (en) 1999-12-30 2002-06-13 Recombinant dehydrated protein in the form of di or oligomer, dimmer, trimmer, quatrumer or pentamer
ZA200205069A ZA200205069B (en) 1999-12-30 2002-06-24 Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins.
US10/185,425 US7385032B2 (en) 1999-12-30 2002-06-28 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US10/871,776 US20040235117A1 (en) 1999-12-30 2004-06-18 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US12/131,478 US20090053252A1 (en) 1999-12-30 2008-06-02 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
CY20081100738T CY1108195T1 (el) 1999-12-30 2008-07-14 Δι-ή ολιγομερες ενος δι-, τρι-, τετρα- ή πενταμερους ανασυνδυασμενων πρωτεϊνων συντηξης
US13/077,512 US20120009211A1 (en) 1999-12-30 2011-03-31 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US13/764,322 US20130202552A1 (en) 1999-12-30 2013-02-11 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US14/264,402 US20150004129A1 (en) 1999-12-30 2014-04-29 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19963859A DE19963859A1 (de) 1999-12-30 1999-12-30 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

Publications (1)

Publication Number Publication Date
DE19963859A1 true DE19963859A1 (de) 2001-07-12

Family

ID=7935052

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19963859A Withdrawn DE19963859A1 (de) 1999-12-30 1999-12-30 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE50015185T Expired - Lifetime DE50015185D1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50015185T Expired - Lifetime DE50015185D1 (de) 1999-12-30 2000-12-20 Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen

Country Status (19)

Country Link
US (6) US7385032B2 (hu)
EP (2) EP1985706A3 (hu)
JP (1) JP5031165B2 (hu)
KR (1) KR100767980B1 (hu)
CN (1) CN100385002C (hu)
AT (1) ATE397076T1 (hu)
AU (1) AU783833B2 (hu)
BR (1) BRPI0017054B1 (hu)
CA (1) CA2395632C (hu)
CY (1) CY1108195T1 (hu)
DE (2) DE19963859A1 (hu)
DK (1) DK1246925T3 (hu)
ES (1) ES2307550T3 (hu)
HU (1) HU229204B1 (hu)
IL (2) IL150215A0 (hu)
PL (1) PL204277B1 (hu)
PT (1) PT1246925E (hu)
WO (1) WO2001049866A1 (hu)
ZA (1) ZA200205069B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2410525A1 (en) * 2000-05-26 2001-11-29 Mochida Pharmaceuticals Co., Ltd. Fas ligand-fused proteins
GB0015426D0 (en) * 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
CA2435000C (en) * 2001-01-18 2014-03-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
BR0214621A (pt) * 2001-11-30 2004-10-13 Ca Nat Research Council Moléculas de automontagem
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
WO2003072713A2 (en) * 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
WO2003095489A1 (en) * 2002-05-08 2003-11-20 Apoxis S.A. Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same
FR2840307B1 (fr) * 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2003277828B2 (en) * 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
SI1606318T1 (sl) * 2003-03-26 2009-12-31 Apogenix Gmbh Izboljšani Fc fuzijski proteini
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
EP1481686A1 (en) * 2003-05-26 2004-12-01 Apoxis SA Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
AU2005291298B2 (en) * 2004-10-01 2012-01-19 Apoxis Sa Method for ex-vivo purging in autologous transplantation
FR2879202B1 (fr) 2004-12-15 2007-02-23 Centre Nat Rech Scient Cnrse Nouveaux ligands multimeriques de cd40, leur procede de preparation et leur utilisation pour la preparation de medicaments
WO2006077232A2 (en) * 2005-01-20 2006-07-27 Apoxis Sa Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
EP1979488A4 (en) * 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR AND CYTOKINE RECEPTOR AGONISTS USED FOR VACCINES AND ANTI-TUMOR IMMUNOTHERAPY
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
SI2310509T1 (sl) 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
CN102612525A (zh) 2009-06-09 2012-07-25 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
KR20120089259A (ko) 2009-08-03 2012-08-09 유니버시티 오브 마이애미 Ｔ 조절 세포의 생체 내 확장 방법
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
EP2518078B1 (en) * 2009-12-15 2020-05-20 Choe, Muhyeon Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
US8932575B2 (en) 2010-09-21 2015-01-13 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
EP2681245B1 (en) 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
NZ700025A (en) * 2012-02-15 2018-07-27 Biocon Ltd A process for detection and optional quantification of an analyte
US9562077B2 (en) 2012-07-11 2017-02-07 Children's Hospital Medical Center Protein complex system for increased immunogenicity and functionality, and methods making and use
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
KR102565827B1 (ko) 2013-01-09 2023-08-11 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
WO2014145355A1 (en) 2013-03-15 2014-09-18 Stone Geoffrey W Composition comprised of antigen linked to a tnf superfamily ligand
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2014179494A1 (en) 2013-04-30 2014-11-06 Colorado State University Research Foundation Sensors and assays for ubiquitin or ubiquitin-like proteins
EP3015860A4 (en) * 2013-05-30 2017-03-29 Muhyeon Choe Super-complex formed by cross-binding between complexes of repeating chain and monomer, and use thereof
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
CN104299540A (zh) * 2013-07-15 2015-01-21 驰众信息技术（上海）有限公司 广告互动播放系统及其广告机终端
NO2776305T3 (hu) 2014-04-23 2018-01-27
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
CN104356233B (zh) * 2014-10-11 2017-09-29 中国科学院微生物研究所 一种人热休克蛋白gp96的scFv抗体及其制备方法与应用
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
RU2745801C2 (ru) 2015-05-04 2021-04-01 Аподжиникс Аг Одноцепочечные белки-агонисты рецептора cd40
RU2018108236A (ru) * 2015-08-12 2019-09-12 Медиммьюн Лимитед Слитые белки на основе gitrl и пути их применения
CA3002587A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
JP6917368B2 (ja) 2015-10-23 2021-08-11 アポジェニックス アーゲー 一本鎖ｃｄ２７受容体アゴニストタンパク質
JP6959229B2 (ja) 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質
CA3003511A1 (en) 2015-10-28 2017-05-04 Apogenix Ag Single-chain tl1a receptor agonist proteins
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017172853A1 (en) 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
CA3033105A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
WO2018115305A1 (en) * 2016-12-22 2018-06-28 Leibniz-Institut für Pflanzengenetik Und Kulturpflanzenforschung (IPK) Oligomeric vaccines from plants by s-tag-s-protein fusions
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
CN112552415B (zh) * 2021-02-22 2021-06-22 北京百普赛斯生物科技股份有限公司 B淋巴细胞刺激因子十二聚体及其制备方法与应用
EP4347665A1 (en) * 2021-05-27 2024-04-10 Beijing Anxinhuaide Biotech. Co., Ltd. A super-trail molecule comprising two trail trimers
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859330A (en) * 1989-12-12 1999-01-12 Epitope, Inc. Regulated expression of heterologous genes in plants and transgenic fruit with a modified ripening phenotype
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
IL134011A0 (en) * 1997-07-18 2001-04-30 Zymogenetics Inc Adipocyte-specific protein homologs
JP4057127B2 (ja) * 1998-02-19 2008-03-05 セイコーエプソン株式会社 アクティブマトリックス基板及びアクティブマトリックス基板の製造方法並びに液晶装置
AU765378B2 (en) * 1998-02-19 2003-09-18 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2003501027A (ja) * 1999-05-27 2003-01-14 ザイモジェネティクス，インコーポレイティド 脂肪細胞補体関連タンパク質同族体ｚａｃｒｐ５
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kishore, Uday [u.a.]: Modular organization of proteins containing C1q-like globular domain. In: Immunopharmacology, 1999, Vol. 42, S. 15-21 *
Terskikh, Alexey V. [u.a.]: "Peptabody": A new type of high avidity binding protein. In: Proc. Natl. Acad. Sci., 1997, Vol. 94, S. 1663-1668 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere

Also Published As

Publication number Publication date
IL150215A (en) 2008-11-26
KR20020089319A (ko) 2002-11-29
PL358456A1 (en) 2004-08-09
IL150215A0 (en) 2002-12-01
EP1985706A2 (de) 2008-10-29
HUP0203628A2 (en) 2003-02-28
US20120009211A1 (en) 2012-01-12
DK1246925T3 (da) 2008-09-01
US20150004129A1 (en) 2015-01-01
PT1246925E (pt) 2008-08-11
CN1526020A (zh) 2004-09-01
BR0017054A (pt) 2003-01-07
AU783833B2 (en) 2005-12-08
AU2367301A (en) 2001-07-16
US20090053252A1 (en) 2009-02-26
US20030053984A1 (en) 2003-03-20
ZA200205069B (en) 2004-03-24
EP1985706A3 (de) 2009-05-13
DE50015185D1 (de) 2008-07-10
CY1108195T1 (el) 2014-02-12
KR100767980B1 (ko) 2007-10-18
ES2307550T3 (es) 2008-12-01
ATE397076T1 (de) 2008-06-15
PL204277B1 (pl) 2009-12-31
WO2001049866A1 (de) 2001-07-12
EP1246925A1 (de) 2002-10-09
CA2395632C (en) 2012-08-28
CN100385002C (zh) 2008-04-30
BRPI0017054B1 (pt) 2017-04-04
EP1246925B1 (de) 2008-05-28
US7385032B2 (en) 2008-06-10
HU229204B1 (hu) 2013-09-30
US20130202552A1 (en) 2013-08-08
JP5031165B2 (ja) 2012-09-19
JP2003518949A (ja) 2003-06-17
US20040235117A1 (en) 2004-11-25
CA2395632A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
DE19963859A1 (de) Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE69633175T2 (de) Multimere proteine
EP1727833B1 (de) Rekombinante polypeptide der mitglieder der tnf ligandenfamilie und deren verwendung
DE60203996T2 (de) Concatamere immunadhäsion
DE69832178T3 (de) Trail bindender rezeptor
DE69332981T2 (de) Methoden zur herstellung löslicher, oligomerer proteine
DE60121808T2 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE69433552T2 (de) An den zelloberflächenrezeptor hek bindendes cytokin
DE10122140A1 (de) Rekombinante Fusionsproteine und deren Trimere
DE69631331T2 (de) Cd40l mutein
CN111328286A (zh) Pd-1和pd-l1结合剂
JP2001506982A (ja) 一酸化窒素産生の制御法
JP2002514418A (ja) 破骨細胞活性の阻害方法
DE69333738T2 (de) Therapeutische domänen des von willebrand-faktor
DE10045592A1 (de) Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
JP2000504586A (ja) ヘテロ二量体を形成するハイブリッドタンパク質
DE60037648T2 (de) Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
DE10247755B4 (de) Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
DE602004008273T2 (de) Pegylierte lösliche gp130-dimere, die sich als medikament eignen
DE102010013887A1 (de) Fusionsprotein und dessen Verwendungen
DE602004011502T2 (de) Rekombinantes fel d 1 allergen
DE69634497T2 (de) Il-6 mutein
Bryde Characterisation of TNF receptor-2 mediated signal initiation and transduction

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: C07K 19/00

8127 New person/name/address of the applicant

Owner name: APOXIS SA, EPALINGES, CH

8130 Withdrawal